{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:15:48Z","timestamp":1790244948419,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13045-018-0695-0","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T09:04:46Z","timestamp":1547456686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors"],"prefix":"10.1186","volume":"12","author":[{"given":"Yongkun","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8450-7583","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"695_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"695_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346\u201354.","journal-title":"Nature"},{"key":"695_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","volume":"9","author":"J Zhang","year":"2009","unstructured":"Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28\u201339.","journal-title":"Nat Rev Cancer"},{"key":"695_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-018-0800-6","volume":"17","author":"HY Tan","year":"2018","unstructured":"Tan HY, Wang N, Lam W, Guo W, Feng Y, Cheng YC. Targeting tumour microenvironment by tyrosine kinase inhibitor. Mol Cancer. 2018;17:43.","journal-title":"Mol Cancer"},{"key":"695_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/cas.13141","volume":"108","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Shan S, Li ZB, Xin LJ, Pan DS, Yang QJ, Liu YP, Yue XP, Liu XR, Gao JZ, et al. CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency. Cancer Sci. 2017;108:469\u201377.","journal-title":"Cancer Sci"},{"key":"695_CR6","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1172\/JCI76094","volume":"125","author":"S Gross","year":"2015","unstructured":"Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest. 2015;125:1780\u20139.","journal-title":"J Clin Invest"},{"key":"695_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10637-014-0176-4","volume":"33","author":"GS Falchook","year":"2015","unstructured":"Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, et al. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs. 2015;33:215\u201324.","journal-title":"Invest New Drugs"},{"key":"695_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc2152","volume":"7","author":"HM Verheul","year":"2007","unstructured":"Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007;7:475\u201385.","journal-title":"Nat Rev Cancer"},{"key":"695_CR9","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/bjh.13333","volume":"170","author":"GP Collins","year":"2015","unstructured":"Collins GP, Eyre TA, Linton KM, Radford J, Vallance GD, Soilleux E, Hatton C. A phase II trial of AZD1152 in relapsed\/refractory diffuse large B-cell lymphoma. Br J Haematol. 2015;170:886\u201390.","journal-title":"Br J Haematol"},{"key":"695_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373:428\u201337.","journal-title":"N Engl J Med"},{"key":"695_CR11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","volume":"30","author":"ES Robinson","year":"2010","unstructured":"Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol. 2010;30:591\u2013601.","journal-title":"Semin Nephrol"},{"key":"695_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","volume":"30","author":"HY Small","year":"2014","unstructured":"Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol. 2014;30:534\u201343.","journal-title":"Can J Cardiol"},{"key":"695_CR13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965\u201372.","journal-title":"J Clin Oncol"},{"key":"695_CR14","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1200\/JCO.2006.07.2066","volume":"25","author":"J Drevs","year":"2007","unstructured":"Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jurgensmeier JM, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:3045\u201354.","journal-title":"J Clin Oncol"},{"key":"695_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s10637-014-0121-6","volume":"32","author":"G Falchook","year":"2014","unstructured":"Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X, Shi H, Fingert H, Sharma S. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs. 2014;32:1181\u20137.","journal-title":"Invest New Drugs"},{"key":"695_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.clml.2013.03.019","volume":"13","author":"HM Kantarjian","year":"2013","unstructured":"Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour EJ, Owen K, Stockman PK, Oliver SD. Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk. 2013;13:559\u201367.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"695_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10637-014-0201-7","volume":"33","author":"C Dittrich","year":"2015","unstructured":"Dittrich C, Fridrik MA, Koenigsberg R, Lee C, Goeldner RG, Hilbert J, Greil R. A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Invest New Drugs. 2015;33:409\u201322.","journal-title":"Invest New Drugs"},{"key":"695_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00280-016-3095-6","volume":"78","author":"K Mross","year":"2016","unstructured":"Mross K, Richly H, Frost A, Scharr D, Nokay B, Graeser R, Lee C, Hilbert J, Goeldner RG, Fietz O, Scheulen ME. A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78:405\u201317.","journal-title":"Cancer Chemother Pharmacol"},{"key":"695_CR19","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s10637-015-0242-6","volume":"33","author":"G Garcia-Manero","year":"2015","unstructured":"Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, et al. Phase 1 dose escalation trial of ilorasertib, a dual Aurora\/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest New Drugs. 2015;33:870\u201380.","journal-title":"Invest New Drugs"},{"key":"695_CR20","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1158\/1078-0432.CCR-10-2144","volume":"17","author":"JR Diamond","year":"2011","unstructured":"Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2011;17:849\u201360.","journal-title":"Clin Cancer Res"},{"key":"695_CR21","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/annonc\/mdm184","volume":"18","author":"O Rixe","year":"2007","unstructured":"Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol. 2007;18:1117.","journal-title":"Ann Oncol"},{"key":"695_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12029-009-9104-9","volume":"40","author":"R Ryanne Wu","year":"2009","unstructured":"Ryanne Wu R, Lindenberg PA, Slack R, Noone AM, Marshall JL, He AR. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer. 2009;40:101\u20138.","journal-title":"J Gastrointest Cancer"},{"key":"695_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/COC.0b013e3182468039","volume":"36","author":"B Estfan","year":"2013","unstructured":"Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2013;36:319\u201324.","journal-title":"Am J Clin Oncol"},{"key":"695_CR24","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/cncr.29234","volume":"121","author":"J Zhong","year":"2015","unstructured":"Zhong J, Ali AN, Voloschin AD, Liu Y, Curran WJ Jr, Crocker IR, Shu HK. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. Cancer. 2015;121:1456\u201362.","journal-title":"Cancer"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0695-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0695-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0695-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T19:13:39Z","timestamp":1578942819000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0695-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0695-0","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]},"assertion":[{"value":"25 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided written informed consent. The protocol was approved by the institutional review boards of the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The consent to publish has been obtained from the participants to report individual patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ZQ Ning and JW Zhang are employees of Shenzhen Chipscreen Biosciences, Ltd. The other authors declared that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"9"}}